Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Biochemical and pharmacological profile of new MAO-A inhibitor: 2614W94

March 3, 1999

Alertec approved in Canada for treatment of narcolepsy

March 3, 1999

Janssen confirms lubeluzole no longer under development

March 3, 1999

FDA issues complete response letter for Rebif BLA

March 3, 1999

German launch announced for Merck's migraine drug

March 2, 1999

Chirocaine considered approvable by FDA, rights return to Chiroscience

March 2, 1999

Favorable phase I results reported for GT-2331 as single doses

March 2, 1999

AHP describes new dopamine autoreceptor agonists in patent literature

March 2, 1999

Orion signs licensing agreement with R.P. Scherer for Zydis apomorphine

March 2, 1999

Oral interferon to enter human trials for MS

March 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...